In this piece, we will look at the stocks that Jim Cramer recently discussed.
In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer commented on Federal Reserve Governor. Lisa Cook and President Trump’s decision to fire her. The matter is currently in court as the Fed official seeks a stay order against Trump’s action. The action carries ramifications for financial markets, and Cramer believes that the matter will eventually be resolved in the Supreme Court:
“Right and as Steve [Steve Liesman] mentioned, look if the facts say that, that there is, that it’s warranted, that this is actually a substative thing, maybe it can trump what the carveout is. But look I just think it’s going to go to the Supreme Court. And this maybe the big case about all these firings and what you can and can’t do. I know that they’ve relied on a series of cases which have increased the power of the executive over the last few years. And that may cut in favor of Trump.”
Our Methodology
To make our list of the stocks that Jim Cramer talked about, we listed down the stocks he mentioned during CNBC’s Squawk on the Street aired on August 28th.
For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13. Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund Holders In Q2 2025: 62
Amgen Inc. (NASDAQ:AMGN) is one of the largest pharmaceutical companies in the world that makes treatments for a variety of ailments such as arthritis, heart problems, and anemia. The shares have gained 10.8% year-to-date on the back of several catalysts, such as positive data about its cancer drug. Cramer’s previous comments about the firm have called it a bargain due to excessive weakness stemming from a weight loss drug trial. This time, he commented on Amgen Inc. (NASDAQ:AMGN)’s coronary artery disease medicine and valuation:
“I take medicine, called Repatha, by the way, which is really good, it’s an Amgen medicine. It lowers cholesterol, and it’s said to be maybe removing plaque from your brain. You want that. But David. It hurts like you wouldn’t believe it, like a banshee. Like a banshee. I mean every Sunday, I’m like aaaaah, now maybe it’s because I’m sensitive. Kind of like your dial up, pssh khwuuum. . .and I wish it were [available in oral form] because boy it’s an amazing medication. I think I wish for Amgen, get than thing in a pill form, everybody in the world would be taking it. Stock’s at 285, sells at 13 times earnings, that’s crazy.”
Here is what Cramer said about Amgen Inc. (NASDAQ:AMGN)’s weight loss drug:
“Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly when it comes to injections any day… So what did we learn when Amgen presented on Monday afternoon? First, the market didn’t like it. The stock sold off. Hard response… There… [was] some genuinely new information too. I’m talking about the Phase 1 trial, data from the separate trial, studying much lower starting doses of MariTide with different escalation schedules, far less vomiting at the low doses…
This is really important because it seems to go down easier when patients start at a lower dose and then ratchet up gradually. So what exactly does this mean for Amgen, the stock? Again, Wall Street was not impressed. When Amgen published this data on Monday afternoon, the stock dropped an incredible 15 points in just a few minutes, finishing the day down almost 6%. But over the past two days, the stock’s recovered a big chunk of the ground that was lost, so maybe there’s something good here…
My bigger concern, we may not see MariTide get FDA approval and make it to the market until late 2027 at best… Amgen’s very confident that their Phase 3 trial will be successful by the time 2027 comes along. Millions of people will probably be taking that Lily weight loss pill. That said, the stock… sold off to the point where I would not bet against it…
I don’t think that new MariTide data is bad enough to justify this decline. And now you’re getting a bargain. That’s right, Amgen’s at a bargain, basement price of 13 times earnings…. And while Lilly’s a great stock that certainly deserves a premium… I think Amgen’s gotten too cheap by comparison.
This is still a big biotech company with mid-single-digit earnings growth expected this year, not to mention potential upside for this GLP-1 drug down the road. But here’s the bottom line: We got plenty of data from this American Diabetes Association conference that ended earlier this week, and I think Amgen’s trial results were misunderstood. The stock did not deserve to get hit this hard. Lily’s still my favorite way to play the GLP-1 story. But if you’re looking for a bargain, you could do a lot worse than Amgen.”
12. Abbott Laboratories (NYSE:ABT)
Number of Hedge Fund Holders In Q2 2025: 69
Abbott Laboratories (NYSE:ABT)’s shares have gained 16.7% year-to-date despite suffering from a major dip in July. The shares sank by 8.5% after the firm’s second-quarter earnings failed to satiate growth-hungry investors. While Abbott Laboratories (NYSE:ABT) beat analyst estimates for earnings and revenue, its decision to keep guidance unchanged was just too much for investors to bear. In his previous comments about the firm, Cramer shared that he was among those who were looking for a guidance raise. This time, he shared what might be a potential catalyst for Abbott Laboratories (NYSE:ABT):
“You know what, my colleague Jeff Marks said this could be good for Abbott. The Binax. Cause it looks like you know if you’re not going to give the COVID vaccine then a lot of people maybe you need the test. So maybe you buy Abbott off the Binax. I don’t know. I think Abbott’s much more of a. . .”
Here’s what Cramer said about Abbott Laboratories (NYSE:ABT) after its earnings:
“Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we’ve long owned for the Charitable Trust… I’d say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook.
A lot of investors, including me, have been hoping they’d raise these numbers, so the stock got clobbered down more than $11 or 8.5%. I thought it might’ve been down $15. That’s what I predicted. It didn’t get that low. As I’ve chronicled many times, this is a stock where we’ve really had to battle over the past several quarters. We’ve kept our faith for the Charitable Trust during some nasty litigation last year. The stock bounced back from that.”
11. Broadcom Inc. (NASDAQ:AVGO)
Number of Hedge Fund Holders In Q2 2025: 156
Broadcom Inc. (NASDAQ:AVGO) is a semiconductor firm known for its smartphone and data center products. The shares have gained 27% year-to-date as they have benefited from the bullishness surrounding AI. Broadcom Inc. (NASDAQ:AVGO) is among the few companies capable of designing chips that can complement NVIDIA’s AI GPUs. Cramer discussed these chips, called ASIC, in his comments:
“Broadcom is going crazy David, what is that. . .
“True but they also help make the ASIC . . .which was kind of slant, this is the alternative, the so called, let’s say the Trainium. . . but, they very specifically at NVIDIA, tell you that if you want to have a chip that does everything, come on you got to, you have to get the Blackwell.”
Previously, the CNBC TV host commented on Broadcom Inc. (NASDAQ:AVGO)’s exposure to Apple and President Trump’s tariffs:
“But, I think that all of these companies you’re seeing there, like Broadcom, yeah they got exposure, but they sell to Apple, I mean, they make it in China, they sell it to Apple, that’s supposed to be okay.”
10. Amazon.com, Inc. (NASDAQ:AMZN)
Number of Hedge Fund Holders In Q2 2025: 335
Amazon.com, Inc. (NASDAQ:AMZN)’s been on Jim Cramer’s radar recently because of its cloud computing division. The firm’s shares fell by 8% earlier this month after its earnings report revealed disappointing growth figures for the AWS cloud computing division. Cramer’s immediate reaction was to criticize Amazon.com, Inc. (NASDAQ:AMZN) for using its in-house Trainium chips, as he believed the firm’s cloud customers were interested in NVIDIA’s GPUs instead. However, has since changed his mind and believes Amazon.com, Inc. (NASDAQ:AMZN) CEO’s Andy Jassy’s approach of balancing costs with computing is the correct one. In these remarks, Cramer commented on Trainium once again:
“. . .let’s say the Trainium, which by the way, just so you know I think the Trainium story at Amazon’s great, but, they very specifically at NVIDIA, tell you that if you want to have a chip that does everything, come on you got to, you have to get the Blackwell.”
Here’s what Cramer previously said about Amazon.com, Inc. (NASDAQ:AMZN) and Trainium:
“Take a look at the Morgan Stanley piece today. The most significant piece of research I’ve read in a long time. By Brian Nowak. Who was the skeptic, on the conference call. That perhaps, there’s, this is, Andy Jassy, of Amazon, perhaps he’s underspending. Okay. Now Andy then just gave a very long soliloquy, there was a very thoughtful, but we we weren’t looking for thoughtful. We were looking for come out and [inaudible].
“What he’s saying is that Amazon is now going to accelerate spending. Amazon’s view, is price-performance is what matters which is why they use their own Trainium. Not performance, but price-performance, because Andy likes to make money, and you know, he makes a lot more money than everybody else. But everyone thought that Microsoft, which maybe aided by OpenAI, accelerated their spend and therefore accelerated their business. This piece, says basically, that was the narrative, I’m going back and saying it’s not, Amazon’s spending more than they have to, 2026 they’re going to get to reaccelerate the growth. 17 and a half percent growth, to 20% growth, AWS.
“The growth fears had to do, and I helped propound this, which was I think, in retrospect, ill-advised by me. That, Amazon was underspending with NVIDIA.”
9. Marvell Technology, Inc. (NASDAQ:MRVL)
Number of Hedge Fund Holders In Q2 2025: 76
Marvell Technology, Inc. (NASDAQ:MRVL) is a semiconductor designer whose shares have lost a whopping 44% year-to-date. If we’re looking for recent negative catalysts, we don’t have to look far, as the stock sank by a whopping 18.5% on Friday. The reason behind the dip was the firm’s fiscal second-quarter earnings report, which saw it guide third-quarter revenue at $2.06 billion to miss analyst estimates of $2.11 billion. For stocks with AI exposure, such as Marvell Technology, Inc. (NASDAQ:MRVL), such a miss is a death knell as it makes investors anxious about AI’s growth prospects. Cramer discussed Marvell Technology, Inc. (NASDAQ:MRVL) ahead of the earnings and commented on its custom AI chips called ASICs:
“True but they [Broadcom] also help make the ASIC, which was, as does Marvell, which was kind of slant, this is the alternative, the so called, let’s say the Trainium, which by the way, just so you know I think the Trainium story at Amazon’s great, but, they very specifically at NVIDIA, tell you tat if you want to have a chip that does everything, come on you got to, you have to get the Blackwell.”
Here are Cramer’s previous thoughts about Marvell Technology, Inc. (NASDAQ:MRVL):
“Marvell Technology’s run by Matt Murphy, and I gotta tell you, Matt, Matt is a gamer. I want you to buy more. I kid you not, I think the stock is going higher. Maybe it goes back to, maybe it goes back to par, which is genuine Wall Street gibberish for $100.”
8. CrowdStrike Holdings, Inc. (NASDAQ:CRWD)
Number of Hedge Fund Holders In Q2 2025: 66
Cybersecurity firm CrowdStrike Holdings, Inc. (NASDAQ:CRWD)’s shares have gained 21.7% year-to-date amidst overall bullish sentiment for the cybersecurity market. This market has weathered the storm that has otherwise hit enterprise software stocks due to AI. CrowdStrike Holdings, Inc. (NASDAQ:CRWD) and other cybersecurity stocks have benefited as the demand for their services grows in an increasingly digital world, and particularly due to AI’s excessive computing requirements. However, the shares dipped by 4% after CrowdStrike Holdings, Inc. (NASDAQ:CRWD)’s earnings report. Here is what Cramer said about the firm:
“Okay so look, I’ve got George Kurtz on today, tonight, and he’s talking about 40% growth in ARR, annualized revenue, that’s the number you need. He has billing, now remember last year July was the time [of the outage] well then he went and offered all these deals and now they’re rolling over and people are signing but they haven’t rolled them all over, and when they do you’re going to have amazing growth. This stock was at 388 last night, as the bozos and morons were hitting the bids. And I was having a big laugh!
“You doubt George Kurtz at your own peril. Okay.”
7. Palo Alto Networks, Inc. (NASDAQ:PANW)
Number of Hedge Fund Holders In Q2 2025: 77
Cybersecurity firm Palo Alto Networks, Inc. (NASDAQ:PANW)’s shares have gained 5.4% year-to-date after significantly trimming their losses in late July and early August due to a 17% dip. The stock fell after Palo Alto Networks, Inc. (NASDAQ:PANW) announced that it would buy cybersecurity firm CyberArk for a $25 billion price tag. Cramer has defended the decision in his previous comments as he believes Palo Alto Networks, Inc. (NASDAQ:PANW) will be able to benefit from the business growth. This time, he recalled a discussion with the firm’s CEO:
“I went to Nikesh Arora from Palo Alto, and basically said, would you please slag George Kurtz, he goes, why would I do that? Thereby the grace of god, I said no cause I just want to have something better to say to David. . .
“But anyway I think that Palo Alto’s great too.”
Here are Cramer’s previous thoughts about Palo Alto Networks, Inc. (NASDAQ:PANW):
“. . .by the way, just so you know, that you know Nikesh Arora identified that identity is incredibly important which is why they spent a fortune on CyberArk. But I think that’s gonna work out.”
6. Chipotle Mexican Grill, Inc. (NYSE:CMG)
Number of Hedge Fund Holders In Q2 2025: 68
The recent dip in Chipotle Mexican Grill, Inc. (NYSE:CMG)’s shares, which saw them fall by 13% and constrained consumer spending in the US has brought the stock back on Jim Cramer’s radar. The CNBC TV host believes that the firm’s menu is just too expensive for diners. This time, he remarked on how the high prices are compounded by high ordering costs as well:
“We’ve been talking about which outfits are doing well, we talked about the Ollie’s, and we talked about Dollar General, Chipotle’s not doing well. Chipotle, a lot of people perceive is, just too expensive. And they are offering kind of a group [inaudible] that comes out to be eight dollars a person, but this is, they talk about cyclicality, and they talk about how tough the economy is for their customers, and I think what that really means is that people want the bargain, they want to go Burlington, they want to go to Olive Garden, and they’re not, Chipotle doesn’t have the sales, they have negative sales.
“But anyway, I just think that, we are stuck with two economies. And its economy says, listen, I’m not gonna pay 18 dollars plus ten dollars DoorDash, 28 dollars, for a burrito bowl. But you know what, I’ll take the five dollar McDonald’s value.”
5. CAVA Group, Inc. (NYSE:CAVA)
Number of Hedge Fund Holders In Q2 2025: 41
CAVA Group, Inc. (NYSE:CAVA)’s shares have lost a whopping 41% year-to-date due to struggling sales that have led to disappointing earnings. August has been a particularly poor month for the stock as it sank by 16.6% following a second-quarter earnings report, which saw CAVA Group, Inc. (NYSE:CAVA) cut its midpoint same-store sales growth guidance by two percentage points to 5%. In his previous comments about the firm, Cramer has maintained that high menu prices are the reason behind CAVA Group, Inc. (NYSE:CAVA)’s struggles. He kept at it this time around as well:
“They’re too high. Costs too much. Versus when you go to Brinker and you get that ten dollar burger with a three for me, they use top shelf. . .”
Here are Cramer’s earlier thoughts about CAVA Group, Inc. (NYSE:CAVA):
“[On recent earnings] Yeah and I do think that when we look at Cava, not mentioned on the call, it’s expensive. You’re talking about 15 smackers versus go and get a smash burger a couple of drinks, a diet coke. Yeah but Chilli’s is ten dollars.
“And Cava, unfortunately is not cheap. It just costs too much for a dinner for a family of five.”
4. Sweetgreen, Inc. (NYSE:SG)
Number of Hedge Fund Holders In Q2 2025: 27
Sweetgreen, Inc. (NYSE:SG) is a fast food company whose shares are among the worst performers in 2025 as they have lost a stunning 71.6% year-to-date. The reason the shares have just been obliterated is Sweetgreen, Inc. (NYSE:SG)’s financial performance, which saw it cut guidance again in August. This guidance cut came as part of the firm’s second-quarter earnings report, which saw Sweetgreen, Inc. (NYSE:SG) miss analyst revenue and EPS estimates of $192 million and -$0.12 by posting $186 million and -$0.20. Crucially, the firm also cut full-year revenue guidance to a $707.5 million midpoint, which was a significant drop over its earlier guidance of $750 million. Cramer asserted that Sweetgreen, Inc. (NYSE:SG) is struggling due to high prices:
“They’re too high. Costs too much. Versus when you go to Brinker and you get that ten dollar burger with a three for me, they use top shelf. . .”
Previously, the CNBC TV host discussed Sweetgreen, Inc. (NYSE:SG)’s business environment:
“Sweetgreen and CAVA… Last week… the salad chain announced that its same-store sales had fallen by 7.6%. Wall Street was looking for a 5.5% decline. Sweetgreen lost 20 cents per share. The analysts were only looking for an 11-cent hit.
… To me, it’s pretty clear what’s going on. CAVA and Sweetgreen have to lower their prices or give us a couple of much lower-priced dishes if they want to turn things around. For now, they’re pricing themselves out of this American market. I get why they’re reluctant to cut prices. What business wants to lower margins?… The problem is, unlike McDonald’s, they’re either maybe too proud or too obtuse, I don’t know, to realize that the consumer’s gotten serious about avoiding high-priced foods, including theirs, even though the food is fresh and good.”
3. Brinker International, Inc. (NYSE:EAT)
Number of Hedge Fund Holders In Q2 2025: 52
Brinker International, Inc. (NYSE:EAT), the casual dining restaurant chain that owns Chili’s and Maggiano’s, has performed well on the stock market in 2025. Its shares have gained 13.3% year-to-date as the firm has benefited from strong business performance. For instance, Brinker International, Inc. (NYSE:EAT)’s latest quarterly results saw the firm report an unbelievable 23.7% same-store sales growth with Chili’s. Cramer believes that affordability lies at the heart of Brinker International, Inc. (NYSE:EAT)’s performance, as he compared the firm to CAVA and Sweetgreens:
“They’re too high. Costs too much. Versus when you go to Brinker and you get that ten dollar burger with a three for me, they use top shelf. . .”
Here are the CNBC TV host’s previous thoughts about Brinker International, Inc. (NYSE:EAT):
“That’s Kevin Hochman. He is so great. What Hochman realized is that America isn’t ready for north of ten bucks. It is delicious. . .they use really good tequila, and I think it’s one of the better places that, I go to with my wife. And we walk out and we say we gave them a beating!
“Well I’ve got Kevin Hochman, who really is the great restaurateur of our time and he does it quietly. I happen to think that Chili’s is a dynamite place to eat, he also owns Maggiano’s, but what Kevin understood was that you got to, you keep it cheap, they’ll come. Value .
“[On how operating margin jumped four points despite low prices] I know, I know, that’s, well cause he’s a great operator and really understands things.”
2. Axon Enterprise, Inc. (NASDAQ:AXON)
Number of Hedge Fund Holders In Q2 2025: 62
Axon Enterprise, Inc. (NASDAQ:AXON) is a well-known company that sells tasers. It has also diversified its business to include software services for law enforcement. The shares have gained 25% year-to-date and are up by a whopping 791% over the past five years. No wonder Cramer called Axon Enterprise, Inc. (NASDAQ:AXON) one of the best-performing stocks all time in these remarks. Previously, he has discussed the firm’s share price levels and advised viewers to gradually build a position. This time, he praised Axon Enterprise, Inc. (NASDAQ:AXON)’s CEO:
“Rick Smith at AXON, probably one of the best performing stocks of all time. That used to be Taser, but now it’s a software-as-a-service for the Justice Department.”
Here’s how Cramer believes one should buy Axon Enterprise, Inc. (NASDAQ:AXON)’s shares:
“Look, I think Rick Smith is great. I have often thought about putting this on my, in the bullpen for this, for the Charitable Trust, but it just won’t quit. I think you have to buy. Look, if you want to buy a 100 shares, buy 25 [on] Monday, and then you gotta wait for it to come down. You can’t just buy it all right here because then I feel like that could be just… It would be just terrible if the stock came in, once again, all-time high today.”
1. The Gap, Inc. (NYSE:GAP)
Number of Hedge Fund Holders In Q2 2025: 44
The Gap, Inc. (NYSE:GAP)’s shares are down by 6.8% year-to-date, primarily on the back of a major selloff in May that saw them sink by 20%. The shares fell in May after the firm flagged that tariffs could lead to it booking as much as $300 million in expenses. Investors were further spooked by the fact that while The Gap, Inc. (NYSE:GAP) did outline the tariff-induced costs, it did not include them in its guidance. The shares slid by an additional 2.8% in August after the firm increased its net tariff expenses to $150 million and $175 million from an earlier $100 million and $150 million. Cramer wondered whether The Gap, Inc. (NYSE:GAP) could make a comeback:
“And then Richard Dickson, can Gap Stores make a comeback? 28 to 20 when he was on last. I’d like to see.”
Here are the CNBC TV host’s previous thoughts about The Gap, Inc. (NYSE:GAP):
“Hey, but how about some other stories? I remember having Richard Dickson, CEO of GAP, on the show right after the old unfortunate Liberation Day tariffs, and after its quarter, stock was crushed. That’s a decent story. Good rally.”
While we acknowledge the potential of GAP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GAP and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
